Technical Analysis for CLBS - Caladrius Biosciences, Inc.

Grade Last Price % Change Price Change
F 1.2 -3.23% -0.04
CLBS closed down 3.23 percent on Friday, September 17, 2021, on 69 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CLBS trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -3.23%
NR7 Range Contraction -3.23%
Oversold Stochastic Weakness -3.23%
Doji - Bullish? Reversal -1.64%
Stochastic Reached Oversold Weakness -1.64%
Oversold Stochastic Weakness -1.64%
Fell Below 20 DMA Bearish -1.64%
Shooting Star Candlestick Bearish -4.00%
Older End-of-Day Signals for CLBS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Caladrius Biosciences, Inc. Description

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Banking Biopharmaceutical Cancer Immunotherapy Diabetes Cancer Immunotherapy Melanoma Cell Therapy Clinical Services Adult Stem Cell Cord Blood Immunotherapy Product Metastatic Melanoma Progenitor Cell Cancer Immunotherapy Product Infarction Myocardial Infarction Neos Acute Myocardial Infarction Treatment Of Metastatic Melanoma

Is CLBS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.88
52 Week Low 1.15
Average Volume 295,118
200-Day Moving Average 1.64
50-Day Moving Average 1.31
20-Day Moving Average 1.25
10-Day Moving Average 1.24
Average True Range 0.05
ADX 17.0
+DI 19.11
-DI 20.60
Chandelier Exit (Long, 3 ATRs) 1.20
Chandelier Exit (Short, 3 ATRs) 1.29
Upper Bollinger Bands 1.32
Lower Bollinger Band 1.18
Percent B (%b) 0.17
BandWidth 11.59
MACD Line -0.02
MACD Signal Line -0.02
MACD Histogram 0.0004
Fundamentals Value
Market Cap 23.28 Million
Num Shares 19.4 Million
EPS -1.87
Price-to-Earnings (P/E) Ratio -0.64
Price-to-Sales 0.00
Price-to-Book 0.75
PEG Ratio -0.03
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.26
Resistance 3 (R3) 1.27 1.25 1.25
Resistance 2 (R2) 1.25 1.24 1.25 1.25
Resistance 1 (R1) 1.23 1.23 1.22 1.22 1.24
Pivot Point 1.21 1.21 1.21 1.21 1.21
Support 1 (S1) 1.19 1.20 1.18 1.18 1.16
Support 2 (S2) 1.17 1.19 1.17 1.15
Support 3 (S3) 1.15 1.17 1.15
Support 4 (S4) 1.14